Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TSX VENTURE EXCHANGE  >  Vaxil Bio Ltd.    VXL   CA92243L1076

VAXIL BIO LTD.

(VXL)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Vaxil Bio : IIROC Trading Resumption - VXL

10/26/2020 | 11:07am EST

VANCOUVER, BC, Oct. 26, 2020 /CNW/ - Trading resumes in:

Company: Vaxil Bio Ltd.

TSX-Venture Symbol: VXL

All Issues: Yes

Resumption (ET): 12:30 PM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions

© Canada Newswire, source Canada Newswire English

All news about VAXIL BIO LTD.
11/25VAXIL BIO : Announces Close of First Tranche of Previously Announced NonBrokered..
AQ
11/24VAXIL BIO : Announces Close of First Tranche of Previously Announced Non-Brokere..
AQ
11/09VAXIL BIO : Announces Non-Brokered Private Placement
AQ
11/09VAXIL BIO : IIROC Trading Resumption - VXL
AQ
11/09VAXIL BIO : IIROC Trading Halt - VXL
AQ
10/26VAXIL BIO : IIROC Trading Resumption - VXL
AQ
10/26VAXIL BIO : Enters Into a Cooperative Research and Development Agreement With U...
AQ
10/26VAXIL BIO : IIROC Trading Halt - VXL
AQ
10/13VAXIL BIO : Initiates Pre-Clinical Study in New Oncology Target
AQ
09/17VAXIL BIO : Provides Update of Conversion of Previously Issued Convertible Debt ..
AQ
More news
Financials
Sales 2019 - - -
Net income 2019 -1,15 M -0,89 M -0,89 M
Net Debt 2019 0,04 M 0,03 M 0,03 M
P/E ratio 2019 -2,70x
Yield 2019 -
Capitalization 9,92 M 7,62 M 7,62 M
EV / Sales 2018 -
EV / Sales 2019 -
Nbr of Employees -
Free-Float 89,7%
Chart VAXIL BIO LTD.
Duration : Period :
Vaxil Bio Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VAXIL BIO LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Managers
NameTitle
David Goren Chairman & Chief Executive Officer
Gadi Levin Chief Financial Officer & Director
Terry F. Plasse Chief Medical Officer
Mordechai Applebaum Director-Research & Development
Ari S. Kellen Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VAXIL BIO LTD.171.43%8
LONZA GROUP AG55.66%44 931
MODERNA, INC.458.18%43 204
CELLTRION, INC.82.04%39 870
IQVIA HOLDINGS INC.9.94%32 568
SEAGEN INC.44.80%29 832